Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 2
1(14.3%)
7Total
Phase 1(6)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06063850Phase 1Recruiting

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Role: lead

NCT06270316Phase 1Recruiting

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

Role: lead

NCT06100276Phase 1Active Not Recruiting

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Role: lead

NCT04120493Phase 1Active Not Recruiting

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

Role: lead

NCT05243017Phase 1Active Not Recruiting

Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease

Role: lead

NCT03293810Completed

Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients

Role: lead

NCT04723680Completed

An Exploration of the Impact of Gene Therapy on the Lives of People With Haemophilia and Their Families

Role: collaborator

NCT03300453Phase 1Completed

Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome

Role: lead

NCT02904772Phase 2Withdrawn

Alipogene Tiparvovec for the Treatment of LPLD Patients

Role: lead

All 9 trials loaded